JP2002531090A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531090A5
JP2002531090A5 JP2000585404A JP2000585404A JP2002531090A5 JP 2002531090 A5 JP2002531090 A5 JP 2002531090A5 JP 2000585404 A JP2000585404 A JP 2000585404A JP 2000585404 A JP2000585404 A JP 2000585404A JP 2002531090 A5 JP2002531090 A5 JP 2002531090A5
Authority
JP
Japan
Prior art keywords
tgf
antibodies
binding
binding protein
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000585404A
Other languages
English (en)
Japanese (ja)
Other versions
JP4813660B2 (ja
JP2002531090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/027990 external-priority patent/WO2000032773A1/en
Publication of JP2002531090A publication Critical patent/JP2002531090A/ja
Publication of JP2002531090A5 publication Critical patent/JP2002531090A5/ja
Application granted granted Critical
Publication of JP4813660B2 publication Critical patent/JP4813660B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000585404A 1998-11-27 1999-11-24 骨鉱化作用を増加するための組成物および方法 Expired - Lifetime JP4813660B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11028398P 1998-11-27 1998-11-27
US60/110,283 1998-11-27
PCT/US1999/027990 WO2000032773A1 (en) 1998-11-27 1999-11-24 Compositions and methods for increasing bone mineralization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011145326A Division JP5691036B2 (ja) 1998-11-27 2011-06-30 骨鉱化作用を増加するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2002531090A JP2002531090A (ja) 2002-09-24
JP2002531090A5 true JP2002531090A5 (https=) 2006-12-07
JP4813660B2 JP4813660B2 (ja) 2011-11-09

Family

ID=22332193

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000585404A Expired - Lifetime JP4813660B2 (ja) 1998-11-27 1999-11-24 骨鉱化作用を増加するための組成物および方法
JP2011145326A Expired - Lifetime JP5691036B2 (ja) 1998-11-27 2011-06-30 骨鉱化作用を増加するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011145326A Expired - Lifetime JP5691036B2 (ja) 1998-11-27 2011-06-30 骨鉱化作用を増加するための組成物および方法

Country Status (18)

Country Link
US (12) US6395511B1 (https=)
EP (3) EP1721979B1 (https=)
JP (2) JP4813660B2 (https=)
CN (2) CN1333828B (https=)
AT (2) ATE481487T1 (https=)
BR (1) BRPI9915679B8 (https=)
CA (1) CA2352532C (https=)
CY (3) CY1106260T1 (https=)
DE (2) DE69933044T3 (https=)
DK (3) DK2261335T3 (https=)
ES (3) ES2350454T3 (https=)
HK (1) HK1044171B (https=)
IL (3) IL143266A0 (https=)
MX (2) MX343200B (https=)
NZ (3) NZ512122A (https=)
PT (3) PT1721979E (https=)
WO (1) WO2000032773A1 (https=)
ZA (1) ZA200104234B (https=)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042926A1 (en) * 1998-10-28 2002-04-11 Matzuk Martin M. Ovary-specific genes and proteins
DE69933044T3 (de) 1998-11-27 2016-11-24 Ucb Pharma, S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3511100A (en) * 1999-03-12 2000-10-04 Regeneron Pharmaceuticals, Inc. Novel nucleic acids and polypeptides
US20030077741A1 (en) * 1999-08-31 2003-04-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA02011808A (es) * 2000-06-01 2003-04-10 Amgen Inc Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
EP1857551A3 (en) * 2000-06-01 2007-11-28 Amgen Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
AU2001272482A1 (en) * 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
WO2002033089A2 (en) * 2000-10-05 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
CA2468125A1 (en) * 2001-10-24 2003-05-01 Dgi Biotechnologies, Inc. Target specific screening and its use for identifying target binders
US7202102B2 (en) * 2001-11-27 2007-04-10 Jds Uniphase Corporation Doped absorption for enhanced responsivity for high speed photodiodes
US7332276B2 (en) * 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
NZ542587A (en) * 2003-03-14 2008-05-30 Celltech R & D Inc Complex comprising a TGF-beta binding protein and a BMP antagonist protein in specific association used to modulate bone mineralization
US20040197828A1 (en) * 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
JP3848288B2 (ja) * 2003-04-25 2006-11-22 キヤノン株式会社 放射線画像撮影装置
EP1632249A4 (en) * 2003-06-05 2007-12-26 Nippon Shinyaku Co Ltd OSTEOGENESIS PROMOTION AMPLIFIER AND SCREENING METHOD THEREFOR
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
WO2005063983A1 (en) * 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
US8188219B2 (en) 2004-01-28 2012-05-29 The Regents Of The University Of California Bone morphogenic protein binding peptide
US8415302B2 (en) 2004-01-28 2013-04-09 The Regents Of The University Of California Surgical applications for BMP binding protein
US8193312B2 (en) 2004-01-28 2012-06-05 The Regents Of The University Of California Bone morphogenic protein binding peptide
US8753660B2 (en) * 2004-11-29 2014-06-17 The Regents Of The University Of California Activating extraction of demineralized bone matrix
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2006135734A2 (en) * 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
KR20190006086A (ko) * 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2009131553A2 (en) * 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
NZ578870A (en) 2007-03-20 2012-01-12 Lilly Co Eli Anti-sclerostin antibodies
EP2171062A1 (en) * 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
CA2698103A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
WO2009122368A2 (en) * 2008-04-02 2009-10-08 Tel Hashomer Medical Research Infrastructure And Services Ltd Biomarker assay and method of use thereof
US8518656B2 (en) 2008-04-02 2013-08-27 Ramot Tel-Aviv University Ltd. Procollagen C-proteinase enhancer (PCPE) biomarker for bone formation
CA2728301A1 (en) * 2008-07-03 2010-01-07 Osteogenex Inc. Vinpocetine and eburnamonine derivatives for promoting bone growth
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
MX2012000214A (es) 2009-06-23 2012-01-25 Univ California Aumento de retencion de bmp.
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2011156373A1 (en) 2010-06-07 2011-12-15 Amgen Inc. Drug delivery device
MX362591B (es) 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
WO2012135035A1 (en) 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
ES2685479T3 (es) 2011-04-19 2018-10-09 Amgen Inc. Método para el tratamiento de la osteoporosis
EP2699293B8 (en) 2011-04-20 2022-07-20 Amgen Inc. Autoinjector apparatus
EP2702408A1 (en) 2011-04-29 2014-03-05 Novartis AG Methods of treating squamous cell carcinoma related applications
CA2842432C (en) 2011-08-04 2022-10-04 Amgen Inc. Method for treating bone gap defects
EP3453711B1 (en) 2011-09-02 2021-08-18 The Regents of the University of California Llp2a- bisphosphonate conjugates for osteoporosis treatment
ES2675035T3 (es) 2011-10-14 2018-07-05 Amgen, Inc Inyector y método de ensamblaje
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3656426B1 (en) 2012-11-21 2023-05-17 Amgen Inc. Drug delivery device
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
SG11201507417RA (en) 2013-03-15 2015-10-29 Amgen Inc Body contour adaptable autoinjector device
CA2904661C (en) 2013-03-15 2022-03-15 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
HUE046702T2 (hu) 2013-03-20 2020-03-30 Genzyme Corp Eljárások üvegcsontbetegség kezelésére
IL292270B2 (en) 2013-03-22 2024-04-01 Amgen Inc Injector and method of assembly
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
MX373358B (es) 2013-10-24 2020-07-06 Amgen Inc Inyector y método de montaje.
ES3062706T3 (en) 2013-10-24 2026-04-13 Amgen Inc Drug delivery system with temperature-sensitive control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
EP3206739B1 (en) 2014-10-14 2021-12-01 Amgen Inc. Drug injection device with visual and audio indicators
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
MA45921A (fr) 2016-08-08 2019-06-19 Amgen Inc Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
US11617737B2 (en) 2016-12-15 2023-04-04 Société des Produits Nestlé S.A. Compositions and methods that modulate vitamin D and bone mineral content in a companion animal
LT3478719T (lt) 2016-12-21 2021-04-12 Mereo Biopharma 3 Limited Antisklerostinų antikūnų naudojimas gydant osteogenesis imperfecta
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
MX2019010671A (es) 2017-03-09 2019-10-21 Amgen Inc Mecanismo de insercion para dispositivo de administracion de farmacos.
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
SG11201907676PA (en) 2017-03-28 2019-09-27 Amgen Inc Plunger rod and syringe assembly system and method
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
AU2018290302B2 (en) 2017-06-23 2024-02-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
IL273323B2 (en) 2017-10-09 2024-10-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
MA50527A (fr) 2017-11-03 2020-09-09 Amgen Inc Système et approches pour stériliser un dispositif d'administration de médicament
IL273664B1 (en) 2017-11-06 2026-02-01 Amgen Inc Full-fledged assemblies and related methods
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
EP3710089A1 (en) 2017-11-16 2020-09-23 Amgen Inc. Autoinjector with stall and end point detection
AU2019237514A1 (en) 2018-03-23 2020-10-08 University Of Massachusetts Gene therapeutics for treating bone disorders
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
MX2021001554A (es) 2018-08-10 2021-04-13 Amgen Inc Metodo de preparacion de una formulacion farmaceutica de anticuerpos.
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
MA53718A (fr) 2018-09-28 2022-01-05 Amgen Inc Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
TWI857975B (zh) 2018-10-02 2024-10-11 美商安進公司 具有內部力傳遞的用於藥物遞送之注射系統
TW202529830A (zh) 2018-10-05 2025-08-01 美商安進公司 具有劑量指示器之藥物遞送裝置
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873566B1 (en) 2018-11-01 2024-11-27 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
CN114630677A (zh) 2019-08-12 2022-06-14 安进公司 抗硬骨素抗体配制品
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
EP4255457A4 (en) * 2020-12-03 2025-05-21 University of Massachusetts DEVELOPMENT OF NEW GENE THERAPEUTIC AGENTS FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
CN113354724A (zh) * 2021-04-28 2021-09-07 蒋青 骨硬化蛋白及其在制备治疗或预防阿尔兹海默症的相关产品上应用
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법
WO2024244941A1 (en) * 2023-05-26 2024-12-05 The University Of Hong Kong Compositions and methods for the treatment of bone loss
AR133302A1 (es) 2023-07-19 2025-09-17 Amgen Inc Métodos de preparación de amortiguador para una formulación de proteína terapéutica
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US649445A (en) * 1899-08-31 1900-05-15 James Alpheus Green Steam-injector for fire-boxes of steam-boilers.
US4018884A (en) 1975-06-26 1977-04-19 Hoffmann-La Roche Inc. Fluorogenic materials and labeling techniques
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4378110A (en) * 1978-04-17 1983-03-29 Greene Ronald W Continuous paper sorting machine
US4528266A (en) 1979-10-01 1985-07-09 George Pieczenik Method of inserting unique DNA sequences into DNA vectors
US4359535A (en) 1979-10-01 1982-11-16 George Pieczenik Autonomously replicating DNA containing inserted DNA sequences
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4427115A (en) * 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) * 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5087571A (en) 1984-06-22 1992-02-11 President And Fellows Of Harvard College Method for providing a cell culture from a transgenic non-human mammal
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
SG64329A1 (en) 1984-11-16 1999-04-27 American Cyanamid Co Antitumor antibiotics (LL-E33288 complex)
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
US4744981A (en) 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE3854823T2 (de) 1987-05-01 1996-05-23 Stratagene Inc Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
ES2061586T3 (es) 1987-10-30 1994-12-16 American Cyanamid Co Analogos disulfuricos de agentes antitumorales ll-e33288.
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
GB8914543D0 (en) 1989-06-23 1989-08-09 Parker David Chemical compounds
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ(ユーケー)リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5359051A (en) 1990-01-11 1994-10-25 Isis Pharmaceuticals Compounds useful in the synthesis of nucleic acids capable of cleaning RNA
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) * 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5387742A (en) 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) * 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0542810A1 (en) * 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗hiv改変抗体および改変抗体の調製方法
US5070108A (en) * 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US6949505B1 (en) * 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
IL108719A0 (en) 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0708659A4 (en) * 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDES
AU7367394A (en) 1993-07-16 1995-02-13 Ontogen Corporation Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
EP0712493A4 (en) 1993-08-03 1997-01-15 Sphinx Pharma Corp METHOD FOR THE PREPARATION AND SELECTION OF NON-PEPTIDE COMPOUNDS FOR PHARMACOLOGICAL USE FROM A UNIVERSAL LIBRARY OF ELEMENTS WITH VARIOUS STRUCTURES
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
AU1068295A (en) 1993-12-09 1995-06-27 Novartis Ag Process for the production of combinatorial compound libraries
SG48166A1 (en) 1993-12-15 1998-04-17 Conbichem Inc Combinatorial libraries and methods for their use
WO1995016712A1 (en) 1993-12-15 1995-06-22 Smithkline Beecham Corporation Compounds and methods
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO1995024186A1 (en) 1994-03-11 1995-09-14 Pharmacopeia, Inc. Sulfonamide derivatives and their use
AU702163B2 (en) 1994-04-29 1999-02-18 Creative Biomolecules, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
JPH10500112A (ja) 1994-05-06 1998-01-06 ファーマコピーア,インコーポレイテッド 組合せ ジヒドロベンゾピラン ライブラリー
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) * 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5738868A (en) * 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
DK0912738T3 (da) * 1996-05-22 2008-11-17 Viventia Biotech Inc Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6610510B1 (en) * 1997-04-29 2003-08-26 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
EP1958962A3 (en) * 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
EP1367124A1 (en) * 1997-08-01 2003-12-03 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) * 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6544485B1 (en) * 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
DE69933044T3 (de) * 1998-11-27 2016-11-24 Ucb Pharma, S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CN1345334A (zh) 1999-01-29 2002-04-17 伊姆克罗尼系统公司 对kdr特异的抗体及其应用
CA2371434A1 (en) 1999-06-09 2000-12-14 Genentech, Inc. Compositions and methods for the treatment of tumor
JP4141095B2 (ja) 1999-10-29 2008-08-27 三洋電機株式会社 半導体装置とその製造方法
JP2003525611A (ja) 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−2分子およびその使用
MXPA02011808A (es) * 2000-06-01 2003-04-10 Amgen Inc Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
AU2001272482A1 (en) 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
CA2632702A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) * 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
NZ533051A (en) 2001-12-06 2006-10-27 Biocontrol Systems Inc Sample collection and testing system
US20030186915A1 (en) * 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
US7332276B2 (en) 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
FR2838379B1 (fr) 2002-04-12 2005-06-24 Valeo Climatisation Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2003304107B2 (en) 2002-11-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
DE10255152A1 (de) 2002-11-26 2004-06-03 Von Langen Ursula Lang Schadstoffsauger
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) * 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
NZ542587A (en) 2003-03-14 2008-05-30 Celltech R & D Inc Complex comprising a TGF-beta binding protein and a BMP antagonist protein in specific association used to modulate bone mineralization
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US8541177B2 (en) 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
EP2114435A1 (en) 2007-02-02 2009-11-11 Novartis AG Modulators of sclerostin binding partners for treating bone-related disorders
NZ578870A (en) 2007-03-20 2012-01-12 Lilly Co Eli Anti-sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 6 (lrp6)을 조정하기 위한 분자 및 방법
US20110044978A1 (en) 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
JP6066912B2 (ja) 2010-10-27 2017-01-25 アムジエン・インコーポレーテツド Dkk1抗体およびその使用方法

Similar Documents

Publication Publication Date Title
JP2002531090A5 (https=)
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
AU2002359851A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
JP2004527212A5 (https=)
CY2019022I2 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
EP2287199A3 (en) Anti-alpha V beta 6 antibodies
EP1378525A3 (en) Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
FI963004L (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
CY2014038I2 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
EP2186884A3 (en) HCV-anti-core monoclonal antibody
EP2322625B8 (en) Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
AU2002349727A1 (en) Hepatitis E virus monoclonal antibodies or the binding fragments of it and the use thereof
EP1516185A4 (en) Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
EP1433792A8 (en) Human receptor proteins, related reagents and methods
AU7960600A (en) Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
IS6143A (is) Peptíð úr TT veiruröð og einsérhæfð mótefni, sem bindast TT veirunni
EP1434799A4 (en) DNA MOLECULES AND RECOMBINANT DNA MOLECULES FOR THE MANUFACTURE OF HUMANIZED MONOCLONAL ANTIBODIES TO S. MUTANS
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.